Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25911601 | 1.00 | TSHR (0.36) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL817926 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL16727813 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL15540189 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL16727811 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL13238229 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL15539608 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL17212370 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL10261997 | 0.86 | TSHR (0.41) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 | |
| SCHEMBL24419237 | 0.85 | ALDH1A1 (0.38) | TSHRSMN1; SMN2ALDH1A1TDP1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10174152-B2 | Process for producing isohexide glycidyl ethers, products thus obtained, and uses thereof | ROQUETTE FRERES (FR) | 2019-01-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10174152-B2 | Process for producing isohexide glycidyl ethers, products thus obtained, and uses thereof | GALE, DDOST, GYPA | TSHR 3974/4885SMN1; SMN2 4436/4885ALDH1A1 3167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.